Boca Pharmacal has received approval from the FDA for Methimazole Tablets USP, the generic version of King Pharmaceutical‘s Tapazole tablets. Methimazole is an antithyroid agent indicated to treat hyperthyroidism. Antithyroid agents inhibit thyroid hormone synthesis. These agents prevent the iodination of tyrosyl residues of thyroglobulin and subsequently inhibit the coupling of the iodotyrosyl residues for the formation of iodothyronines. Methimazole does not inactivate existing T4 and T3 and does not interfere with the activity of exogenously administered thyroid hormone.
Methimazole Tablets USP will be available in 5mg and 10mg dosage strengths.
For more information visit www.bocapharmacal.com.